Next 10 |
Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to plan Solid cash position allows cash visibility until at least late 2024 aided by non-dilutive funding and a c...
CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancer Strong preclinical data generated with CT-02 against NEK7 CT-05 potential best-in-class profile in high potential / partially de-risked PKCӨ protein pathway Webcast to take...
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical ...
WROCŁAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment for cancer and autoimmune diseases, reports its financial results for ...
WROCŁAW, Poland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE: CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to develop novel sm...
WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, today announces that it has selected ...
WROCŁAW, Poland, May 05, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces it will host a virtual Research and Development...
CT-01 compounds induce degradation of GSPT1, SALL4 and another as yet undisclosed neo-substrate The unique degradation profile supports the strong competitive potential of the program Compelling pre-clinical data generated demonstrating HCC tumor regression CT-...
WROCLAW, Poland, April 11, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces that it has been invited to participate in the 8 ...
Data confirm strong anticancer activity of two lead compounds in CT-01 program Results support advancement of CT-01 compounds towards IND expected in late 2022 WROCŁAW, Poland, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceut...
News, Short Squeeze, Breakout and More Instantly...
Qwest Corporation 7.00% Notes due 2052 Company Name:
CTX Stock Symbol:
NYSE Market:
Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to plan Solid cash position allows cash visibility until at least late 2024 aided by non-dilutive funding and a c...
CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancer Strong preclinical data generated with CT-02 against NEK7 CT-05 potential best-in-class profile in high potential / partially de-risked PKCӨ protein pathway Webcast to take...
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical ...